Novartis India Q1 FY26 | FY25 – ₹352 Cr Sales, 27% OPM, 70% Swiss Parent Stake & FD Income Larger Than R&D: Big Pharma Muscle or Indian Side-Hustle?
1. At a Glance
Novartis India (NIL) is a ₹2,164 Cr midcap pharma with a global giant as its daddy, but in India it behaves less like a pharma innovator and more like a fixed deposit investor. CMP ₹876, P/E 21x, dividend yield 2.85%. FY25 sales: ₹352 Cr, PAT ₹103 Cr, OPM 27%. Sounds fancy until you realise: 99% of revenue is “traded goods” (a.k.a. imports and resales). Debt is ₹5 Cr (basically zero). Promoter holding is 70.7% (Swiss Novartis AG). Other income (₹62 Cr in FY24) is nearly 60% of EBIT.
In short: margins are world-class, sales growth is reverse gear. Stock is down 21% in 1 year. Question: are you buying Indian pharma muscle or just holding a Swiss royalty cheque?
2. Introduction
Imagine Sachin Tendulkar’s son Arjun: huge brand name, giant expectations, but in domestic cricket still proving himself. That’s Novartis India. Parent is a $45 Bn global pharma juggernaut. Indian arm? ₹352 Cr annual sales – smaller than the coffee budget of Apollo Hospitals.
Novartis India is basically a distribution company. It doesn’t “make” blockbuster drugs here – it imports them. Voveran (pain), Sandimmun & Certican (transplants), Tegrital & Exelon (neuro). But thanks to the National List of Essential Medicines (NLEM) price cuts, FY24 revenue fell 12%.
Meanwhile, the transplant drugs grew 11% – the one healthy organ in this body. And while topline shrank, bottom line held strong because FD interest and tax refunds padded profit. That’s not pharma research, that’s Treasury Management 101.
So is Novartis India a pharma play, or a pseudo-NBFC with a pill side-hustle?
3. Business Model – WTF Do They Even Do?
Core: Import branded drugs from global Novartis, distribute in India.
Distribution tie-up: In FY22, Dr Reddy’s got exclusive sales rights for key brands like Voveran & Methergine – so Novartis India outsourced even the selling.
Revenue model: 99% traded goods (buy-sell), only 1% “others.”
Development hub: Their Hyderabad/Mumbai R&D centers? Owned by parent, not listed entity. India subsidiary just shows them off like borrowed jewellery at a shaadi.
So yes, it’s less “pharma innovation” and more “import-and-distribute.”
4. Financials Overview
Source table
Metric
Latest Qtr (Q1 FY26)
YoY Qtr (Q1 FY25)
Prev Qtr (Q4 FY25)
YoY %
QoQ %
Revenue
₹88 Cr
₹92 Cr
₹84 Cr
-4.3%
+4.8%
EBITDA
₹27 Cr
₹24 Cr
₹24 Cr
+12.5%
+12.5%
PAT
₹28 Cr
₹26 Cr
₹29 Cr
+7.7%
-3.4%
EPS (₹)
11.2
10.4
11.9
+7.7%
-5.9%
Annualised EPS ≈ ₹45 CMP / EPS ≈ 876 / 45 ≈ 19.5x
Commentary: Sales stagnant, but OPM 27–30%. That’s not medicine margins, that’s luxury handbags. Profit steady thanks to other income cushions.
